This study is open to adults 18 years and older with advanced or metastatic non-smallcell lung cancer. People can join the study if they have tumours with HER2 mutations andhave not yet received any systemic therapy including chemotherapy for advanced ormetastatic lung cancer. The purpose of this study is to find out whether a medicinecalled zongertinib (BI 1810631) can slow down the worsening of advanced non-small celllung cancer better than the standard treatment available. Zongertinib may slow cancercell growth by inhibiting HER2. This would prolong cancer re-occurrence and increasesurvival. Current standard treatment is pembrolizumab plus platinum-pemetrexedchemotherapy.Participants are put into 2 groups by chance. One group receives zongertinib at regulartimes throughout the study and the other group receives infusions of pembrolizumab,pemetrexed and cisplatin or carboplatin (pembrolizumab plus platinum-pemetrexedchemotherapy) into a vein.Participants may be in the study up to a
This study is open to adults 18 years and older with advanced or metastatic non-smallcell lung cancer. People can join the study if they have tumours with HER2 mutations andhave not yet received any systemic therapy including chemotherapy for advanced ormetastatic lung cancer. The purpose of this study is to find out whether a medicinecalled zongertinib (BI 1810631) can slow down the worsening of advanced non-small celllung cancer better than the standard treatment available. Zongertinib may slow cancercell growth by inhibiting HER2. This would prolong cancer re-occurrence and increasesurvival. Current standard treatment is pembrolizumab plus platinum-pemetrexedchemotherapy.Participants are put into 2 groups by chance. One group receives zongertinib at regulartimes throughout the study and the other group receives infusions of pembrolizumab,pemetrexed and cisplatin or carboplatin (pembrolizumab plus platinum-pemetrexedchemotherapy) into a vein.Participants may be in the study up to a
